RESUMO
Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13, was used to successfully induce remission of chronic, disseminated eczema herpeticum in a six-year-old girl who has DOCK8-deficiency hyper-IgE syndrome. The patient was started on 200 mg of dupilumab administered once every four weeks. The patient had achieved complete resolution of all active herpetic lesions by the time her third dose was due. During the course of three months, she had not developed any new lesions, and significant improvement of the patient's skin, scalp, hair restoration, and nails was appreciated.
RESUMO
Background As a well-documented fact, metastatic brain tumors are the most common cause of brain tumors in adults, with an incidence of 9-17%, based on various studies, although it was thought to be higher. The aim of this study was to describe recorded cases of metastatic brain tumors in the adult population of a tertiary care and oncology center in Jeddah, Saudi Arabia. Methods This study was conducted at King Abdulaziz Medical City (KAMC) at King Khalid Hospital in Jeddah, Saudi Arabia, including records from January 2016 to December 2020. The study implemented a retrospective cohort design to fulfill its aim. A data collection sheet containing demographic data such as age and gender, and information pertaining to the primary pathology, multiplicity, and survival outcome was used. Results A total number of 213 patients were enrolled in this study. Overall, 68.1% of the sample comprised of females. Approximately two-thirds (61.9%) of the patients' imaging results revealed multiplicity, whereas the remaining third (38.1%) had solitary lesions. The estimated overall survival median after the diagnosis of brain metastasis was six months (95% CI: 5.5-6.5). Conclusion We recommend conducting a nationwide study to better understand the incidence in accordance to geographical and gender differences. We can further expand our research to include other institutes in Saudi Arabia, and include important predictors such as time from the diagnosis of primary pathology to brain metastasis, disease progression cost, and disease progression in the months prior to the patients' death.
RESUMO
Multisystem inflammatory syndrome in children (MIS-C) is a new emerging severe form of coronavirus disease 2019 (COVID-19) that recently has been recognized in April 2020 in the United States and the United Kingdom. MIS-C is an uncommon condition that mainly affects children who previously had a COVID-19 infection, and it can have serious outcomes if left untreated properly. The full clinical spectrum of this disease is yet not fully determined or understood. Here, we report a case of a 12-year-old girl, previously medically free, who presented to the emergency room complaining of shortness of breath and dizziness for two days. The patient was confirmed to have a COVID-19 infection in the workup. Laboratory studies showed elevated inflammatory markers, leukopenia, and elevated liver enzymes. Upon admission, the patient developed a persistent fever with a spike of 40ºC, not resolved with antibiotics or anti-inflammatory drugs. This was managed with intravenous immunoglobulin (IVIG) followed by steroids but did not show dramatic change initially. The patient eventually improved with management and was discharged.
